期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 78, 期 4, 页码 384-407出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.05.024
关键词
coronary artery bypass graft; coronary artery disease; drug-eluting stent; percutaneous coronary intervention
资金
- Japanese Circulation Society
- Fukuda Founda-tion for Medical Technology
Over the past 40 years, percutaneous coronary intervention has become a standard treatment option for patients with advanced coronary artery disease. However, the roles of percutaneous coronary intervention and coronary artery bypass graft surgery in different patient populations continue to be debated, with personalized medicine emerging as an important consideration. Advancements in technology and pharmaceuticals will continue to shape the conversation around the best treatment strategies for individual patients.
Over the last 4 decades, percutaneous coronary intervention has evolved dramatically and is now an acceptable treat-ment option for patients with advanced coronary artery disease. However, trialists have struggled to establish the respective roles for percutaneous coronary intervention and coronary artery bypass graft surgery, especially in patients with multivessel disease and unprotected left-main stem coronary artery disease. Several pivotal trials and meta-analyses comparing these 2 revascularization strategies have enabled the relative merits of each technique to be established with regard to the type of ischemic syndrome, the coronary anatomy, and the patient's overall comorbidity. Precision medicine with individualized prognosis is emerging as an important method of selecting treatment. However, the never-ending advancement of technology, in conjunction with the emergence of novel pharmacological agents, will in the future continue to force us to reconsider the evolving question: Which treatment strategy is better and for which patient? (J Am Coll Cardiol 2021;78:384-407) (c) 2021 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据